Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of RAG-01 Monotherapy and RAG-01 in Combination With Chemotherapy in Intermediate/High-risk Patients With Non-muscle Invasive Bladder Cancer (NMIBC).

NCT07777848 is registered in ClinicalTrials.gov with Ractigen Therapeutics. as lead sponsor.

NCT NCT07777848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07777848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of RAG-01 Monotherapy and RAG-01 in Combination With Chemotherapy in Intermediate/High-risk Patients With Non-muscle Invasive Bladder Cancer (NMIBC).
Lead sponsor
Ractigen Therapeutics.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2029
Enrollment
114 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer (nmibc)